Acute Myeloid Leukemia Treatment
OncoVerity Inc. focuses on clinical research in acute myeloid leukemia, with studies centered on newly diagnosed patients who are not candidates for intensive chemotherapy. The sponsor’s trial portfolio includes combination approaches built around azacitidine and other background therapies for this hematologic malignancy.
- Newly diagnosed AML
- Non-intensive treatment settings
- Hematologic oncology
The research activity reflects a strong interest in treatment options for patients requiring less intensive therapeutic strategies in blood cancer care.
CD70-Targeted Oncology
The sponsor’s studies include cusatuzumab, an anti-CD70 monoclonal antibody explored in AML as part of targeted therapeutic combinations. This places emphasis on CD70-directed therapy within the broader field of oncology drug development.
- Anti-CD70 monoclonal antibody
- Targeted immuno-oncology
- Leukemia-directed biologics
These trials examine the role of targeted biologic agents in myeloid malignancies.
Combination Regimens in Hematology
OncoVerity’s clinical program evaluates combination therapy strategies pairing cusatuzumab with established agents such as venetoclax and azacitidine. The research interest is concentrated on regimen development for patients with acute myeloid leukemia.
- Venetoclax-based combinations
- Hypomethylating agent combinations
- Frontline AML therapy
This area highlights therapeutic exploration in multi-agent leukemia treatment.
Multicenter Clinical Oncology
The sponsor conducts multicenter research across sites in North America and another active country, supporting patient access to studies in acute myeloid leukemia. The active trial network spans multiple collaborating research sites.
- International trial participation
- Collaborative oncology sites
- Recruiting AML studies
Its clinical activity is concentrated in oncology with a specific emphasis on hematologic cancer research.
